Welcome to an exploration of the potential significance of news releases in the world of stocks. In this article, we examine four NASDAQ-listed stocks that have recently garnered attention due to news events, considering how these news releases can act as catalysts for potential breakouts. The impact of news on market sentiment and price movements can offer enticing opportunities for investors, particularly in the world of penny stocks. As we delve into the dynamics of these news-driven stocks, we uncover the allure they hold for traders seeking substantial returns.
Smart For Life Inc. (NASDAQ: SMFL) is a dynamic player in the health and wellness sector, carving a niche as a global leader in marketing and manufacturing nutritional foods and supplements.
With a keen focus on health and wellness replacement products, SMFL offers a diverse range of nutritional bars, cookies, soaps, shakes, vitamins, and supplements. As a company, SMFL is executing a strategic Buy-and-Build approach with serial accretive acquisitions. This strategy aims to create a vertically integrated company by aggregating businesses generating a minimum of $300 million in revenues by the fourth quarter of 2026.
SMFL made a significant announcement on Aug. 1, announcing their decision to effect a 1-for-3 reverse stock split, taking effect on August 2, 2023.
As a company engaged in the development, marketing, manufacturing, acquisition, and sale of a wide range of nutritional and related products with a strong emphasis on health and wellness, SMFL has been executing a visionary Buy-and-Build strategy. The strategy aims to create a vertically integrated company, aggregating businesses generating a minimum of $300 million in revenues by the fourth quarter of 2026.
The reverse stock split decision is not only aimed at maintaining SMFL’s’s compliance with the minimum bid price requirement for its common stock listed on the NASDAQ Capital Market, but it is also part of a larger strategic plan. SMFL intends to support future acquisition financings, including multiple accretive acquisitions currently and prospectively in its pipeline.
Through the reverse stock split, SMFL seeks to optimize its capital structure, enhance financial flexibility, and potentially attract a broader universe of investors. By consolidating shares at a 1-for-3 ratio, SMFL aims to increase the bid price of its common stock, which may lead to heightened investor interest and improved market liquidity.
Darren Minton, Chief Executive Officer of Smart for Life, expressed confidence in SMFL’s’s transformation, stating, “We have undergone a significant transformation of the Company, which we believe has set the stage for sustainable organic growth and positions us to execute on additional, highly accretive acquisitions. Nevertheless, the overall capital markets remain challenging, and we believe this reverse split will allow us to maintain Nasdaq compliance, tighten the public float in our stock, and attract a broader universe of investors. Overall, we are highly encouraged by the outlook for the business and remain steadfast in achieving our near-term goal of $100 million in annualized revenues, as well as sustained profitability.”
As SMFL continues to execute its vision, including developing proprietary products and acquiring profitable companies with encompassing brands, manufacturing, and distribution channels, it remains steadfast in achieving its near-term goal of reaching $100 million in annualized revenues and sustaining profitability.
Smart For Life Inc. (NASDAQ: SMFL) has taken a significant step with its announcement of a 1-for-3 reverse stock split. As SMFL navigates the dynamic Health & Wellness sector, investors are closely monitoring SMFL’s strategic moves and positioning, recognizing the potential for growth and long-term success. This announcement represents a crucial development in SMFL’s ongoing efforts to enhance shareholder value and drive the company’s growth trajectory.
Trust Stamp (NASDAQ:IDAI) is a worldwide provider of artificial intelligence-backed identity services that could be deployed across a range of sectors. The services are applicable in banking, regulatory compliance, finance, real estate, humanitarian services, and communications, among others.
The technology from Trust Stamp provides organizations with the power of highly advanced biometric identity solutions that help limit fraud, protect personal data and personal privacy, and boost operational efficiency. The company has operations in seven countries spread across Africa, Europe, North America, and Africa. The stock is listed on the NASDAQ Capital Market.
On August 2, Trust Stamp announced that on July 25, 2023, the United States Patent Office had issued a patent to Trust Stamp titled “Systems and Methods for Privacy-Secured Biometric Identification and Verification”. It was the 16th patent that was issued to the company; however, it also has 15 patent applications that are still pending. One of those 15 patents has already been approved but has not been issued yet.
The Chief Science Officer of Trust Stamp, Dr. Norman Poh, spoke about the latest development. He noted that there was now an elevated focus on the protection of data security and privacy for the end users of biometric services.
He noted that it had been a core consideration of the product development process at Trust Stump since the company was established. He went on to add that over the past six years, the company has invested heavily in research and development so as to create a strong foundation for its products.
Poh also stated that the investment made by the company in its research and development activities was bearing fruit. That was apparent from the patent issuances to the company and also in the acceleration in the implementation of its technology. The company’s customer base in the financial services sector has also been expanding.
WaveDancer Inc. (NASDAQ:WAVD) is well-known for being the parent company of Tellenger, which is headquartered in Fairfax, Virginia. It has been assisting commercial and federal customers since as far back as 1979. It provides cybersecurity, modernization, and software development services to organizations so as to help them meet their business goals through the deployment of suitable technology.
Due to the products’ consistency in delivering high-level metrics, Tellenger’s software development processes have received a CMMI Level 3 evaluation. The company can help clients in a range of spaces, starting from SaaS implementations to cloud migrations and from business process re-engineering to much more, to boost productivity and hit their KPIs.
On August 2, Tellenger announced that it had bagged a contract spanning seven years from a large systems integrator. The aim of the contract would be to continue supporting a significant financial program of a large United States government (USG) customer. Tellenger revealed that it expected the revenues from the contract to be between $12 million and $15 million throughout the course of the duration.
Tellenger has been a subcontracting partner to the USG customer for a long time and had originally been tasked with the job of modernizing its financial systems. The modernization initiative was meant to allow for higher reliability and easier maintenance. The latest contract signed by Tellenger would see the continuation of progress on that particular front in terms of enhancements. There are plans to add new functionalities as well to advance those applications.
“The work we are doing in collaboration with our teaming partner will ready this critical government financial application for the future,” said Stan Reese, Tellenger’s President and CEO. “This substantial new award reinforces Tellenger’s position as a leader in modernization and systems engineering. It is a testament to the significant value we bring to customers and partners through a commitment to delivering meaningful ROI with everything we do.”
FSD Pharma Inc. (NASDAQ:HUGE), a biotechnology company, currently has two candidates that are in different stages of development. Its fully owned subsidiary unit, Lucid Psychss Inc., is currently involved in the development and research related to its lead compounds, UNBUZZD and Lucid-MS.
It ought to be noted that no clinical trials have yet been undertaken for UNBUZZD, and the product is yet to be scientifically proven or tested. Lucid-MS is a molecular compound that has been identified as potentially treating neurodegenerative conditions.
In the latest development, FSD Pharma has signed a definitive agreement with Celly Nutrition Inc. Through this agreement, Celly Nutrition would get the exclusive rights to the recreational application from FSD Pharma for its alcohol misuse technology.
Celly Nutrition would then launch FSD Pharma’s path-breaking rapid alcohol detoxification drink, UNBUZZD. UNBUZZD had been created by the scientists at the company and through expert clinical research. Grand View Research Inc. noted that the worldwide hangover cure products market could hit $6.18 billion in size by 2030. That would work out to a CAGR of 14.8% from 2021 through 2028.
The Chief Executive Officer and Executive Co-Chairman of the Board at FSD Pharma, Zeeshan Saeed, spoke about the latest development as well. He noted that it was a major development for the company since it was a step in the right direction in commercializing FSD Pharma’s science. He went on to note that the company boasted the brightest people who would be leading the efforts for the commercialization of the product and its rollout.
He referred to the fact that the same team had been responsible for the considerable success that FSD Pharma had enjoyed with the product Celsius. The team in charge of UNBUZZD is highly accomplished and experienced. As per the terms of the agreement, the company would get a 7% royalty from Celly Nutrition from total revenues. However, once the amount hits $250,000,000 in total, the rate would be cut to 3%.
Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) has been retained by the SMFL to assist in the production and distribution of content. ‘CGR’ is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR is not a fiduciary by virtue of any persons use of or access to this content.